Preferences and consequences in therapy decision-making: tiotropium bromide plus olodaterol vs ICS-containing regimens in COPD patients in the Portuguese primary care setting: an observational, cross-sectional study (TIOLCOR Study)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/48434
• EU PAS number:
  EUPAS35841
• Study ID:
  48434
• Official title and acronym:
  Preferences and consequences in therapy decision-making: tiotropium bromide plus olodaterol vs ICS-containing regimens in COPD patients in the Portuguese primary care setting: an observational, cross-sectional study (TIOLCOR Study)
• DARWIN EU® study:
  No
• Study countries:
  Portugal
• Study description:
  What are the differences between patients prescribed a new maintenance treatment for COPD with tiotropium/olodaterol (TIO/OLO) or ICS-containing regimens in terms of sociodemographic, anthropometric and clinical characteristics? - STUDY WAS CANCELLED -
• Study status:
  Planned

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Planned: 30/10/2020

Study start date

Planned: 30/06/2021

Date of final study report

Planned: 30/06/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable